Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Nassim, Roland ^a   Mansure, Jose Joao ^a   Chevalier, Simone ^a   Cury, Fabio ^b   Kassouf, Wassim ^a  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; PROTEIN P27;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; TREATMENT OUTCOME;

CELL LINE, TUMOR; G1 PHASE; G2 PHASE; HUMANS; RADIATION TOLERANCE; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

MAMMALIA; MUS;

EID: 84879176387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065257     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10-29.
2. Konety BR, Joyce GF, Wise M, (2007) Bladder and upper tract urothelial cancer. J Urol 177: 1636-1645.
3. Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, et al. (2007) Radiotherapy for bladder cancer. Urology 69: 80-92.
4. Ron E, (2003) Cancer risks from medical radiation. Health Phys 85: 47-59.
5. Mattsson A, Ruden BI, Hall P, Wilking N, Rutqvist LE, (1993) Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst 85: 1679-1685.
6. Lieberman HB, (2008) DNA damage repair and response proteins as targets for cancer therapy. Curr Med Chem 15: 360-367.
7. Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, et al. (1998) A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. The Journal of urology 160: 1673-1677.
8. Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, et al. (2003) Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. International journal of radiation oncology, biology, physics 56: 726-733.
9. Cantley LC, (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
10. Morgensztern D, McLeod HL, (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803.
11. Diaz De Stahl T, Segersten U, Malmstrom PU, (2008) Molecular genetics of bladder cancer: an update. Minerva Urol Nefrol 60: 205-216.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England journal of medicine 356: 2271-2281.
13. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, et al. (2009) Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer biology & therapy 8: 2339-2347.
14. Albert JM, Kim KW, Cao C, Lu B, (2006) Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5: 1183-1189.
15. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, et al. (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24: 5414-5422.
16. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, et al. (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66: 10040-10047.
17. Li HF, Kim JS, Waldman T, (2009) Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiation oncology 4: 43.
18. Xia S, Zhao Y, Yu S, Zhang M, (2010) Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer biotherapy & radiopharmaceuticals 25: 317-323.
19. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, et al. (2006) Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. The Journal of urology 175: 1133-1137.
20. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, et al. (1995) Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. The Journal of urology 154: 1532-1538.
21. Deng R, Tang J, Ma JG, Chen SP, Xia LP, et al. (2011) PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 30: 944-955.
22. Zhan M, Han ZC, (2004) Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19: 915-923.
23. Ram R, Uziel O, Eldan O, Fenig E, Beery E, et al. (2009) Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 15: 914-923.
24. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, et al. (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12: 4119-4126.
25. Bussink J, van der Kogel AJ, Kaanders JH, (2008) Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9: 288-296.
26. Jackson SP, (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23: 687-696.
27. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, et al. (2009) Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha. Oncology reports 21: 801-807.
28. Terasima T, Tolmach LJ, (1963) Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophysical journal 3: 11-33.
29. Sinclair WK, Morton RA, (1965) X-Ray and Ultraviolet Sensitivity of Synchronized Chinese Hamster Cells at Various Stages of the Cell Cycle. Biophysical journal 5: 1-25.
30. Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. International journal of radiation oncology, biology, physics 59: 928-942.
31. Sinclair WK, (1968) Cyclic x-ray responses in mammalian cells in vitro. Radiation research 33: 620-643.
32. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, et al. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287: C281-291.
33. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, et al. (2009) mTOR inhibitors rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer.
34. Law M, Forrester E, Chytil A, Corsino P, Green G, et al. (2006) Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer research 66: 1070-1080.
35. Toyoshima H, Hunter T, (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74.
36. Kaufmann WK, Paules RS, (1996) DNA damage and cell cycle checkpoints. FASEB J 10: 238-247.
37. Cayrol C, Knibiehler M, Ducommun B, (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320.
38. Zhang H, Xiong Y, Beach D, (1993) Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897-906.
39. Jones JM, Cui XS, Medina D, Donehower LA, (1999) Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 10: 213-222.
40. Coqueret O, (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends in cell biology 13: 65-70.
41. Samuel T, Weber HO, Funk JO, (2002) Linking DNA damage to cell cycle checkpoints. Cell cycle 1: 162-168.
42. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, et al. (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proceedings of the National Academy of Sciences of the United States of America 96: 1002-1007.